DME drug continues to impress

Article

iCo-007, the experimental intravitreal injection for the treatment of diabetic macular oedema (DME), has produced pleasing interim trial results and been approved to progress to the third stage of the Phase I study, according to a statement released by the drug's licence holder, iCo Therapeutics Inc.

iCo-007, the experimental intravitreal injection for the treatment of diabetic macular oedema (DME), has produced pleasing interim trial results and been approved to progress to the third stage of the Phase I study, according to a statement released by the drug's licence holder, iCo Therapeutics Inc.

iCo-007 - designed and discovered by ISIS Pharmaceuticals Inc for the treatment of DME and diabetic retinopathy (DR) - is a second-generation antisense inhibitor, which targets not vascular endothelial growth factor (VEGF) but the Raf isoform c-Raf kinase mRNA, and may also prove to be a viable treatment for certain oncology indications.

The open-label, dose-escalation study, which is assessing the mechanism of iCo-007 in sufferers of diffuse DME and not healthy volunteers, has a primary endpoint of establishing safety and tolerability in diffuse DME patients; the study will also monitor pharmacokinetics, retinal thickness and visual acuity. At this mid-point of the trial, administration of iCo-007 is not associated with any serious adverse events.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.